Home › Merck Statement on FDA Advisory Committee Meeting for Suvorexant
 

Keywords :   


Merck Statement on FDA Advisory Committee Meeting for Suvorexant

2013-05-23 00:28:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Mercks investigational medicine to treat insomnia. Language:  English Contact HTML:  MerckMedia:Pam Eisele, 908-423-5042orTracy Ogden, 267-305-2301orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: statement meeting committee advisory

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Atlantic Tropical Weather Outlook
05.10Tropical Storm Milton Update Statement
05.10Summary for Tropical Storm Milton (AT4/AL142024)
05.10Eastern North Pacific Tropical Weather Outlook
05.10Tropical Depression Fourteen Graphics
05.10Tropical Depression Fourteen Forecast Discussion Number 1
05.10Tropical Depression Fourteen Wind Speed Probabilities Number 1
05.10Tropical Depression Fourteen Public Advisory Number 1
More »